

## Zambia support for Measles vaccine

This decision letter sets out the programme terms of a programme.

<b>1. Country:</b> Zambia									
<b>2. Grant number:</b> 16-ZMB-09a-X									
<b>3. Date of decision letter:</b> 19 November 2015									
<b>4. Date of the partnership framework agreement:</b> 22 October 2014									
<b>5. Programme title:</b> New vaccine support (NVS), Measles second dose Routine									
<b>6. Vaccine type:</b> Measles									
<b>7. Requested product presentation and formulation of vaccine:</b> Measles, 10 doses per vial, LYOPHILISED									
<b>8. Programme duration<sup>1</sup>:</b> 2012 - 2016									
<b>9. Programme budget (indicative):</b> (subject to the terms of the partnership framework agreement, if applicable)									
<table border="1" style="margin-left: auto; margin-right: auto; border-collapse: collapse;"> <thead> <tr> <th style="width: 20%;"></th> <th style="width: 20%;">2012-2015</th> <th style="width: 20%;">2016</th> <th style="width: 40%;">Total<sup>2</sup></th> </tr> </thead> <tbody> <tr> <td style="padding: 2px;">Programme budget</td> <td style="padding: 2px;">US\$ 615,018<sup>3</sup></td> <td style="padding: 2px;">US\$ 0</td> <td style="padding: 2px;">US\$ 615,018</td> </tr> </tbody> </table>		2012-2015	2016	Total <sup>2</sup>	Programme budget	US\$ 615,018 <sup>3</sup>	US\$ 0	US\$ 615,018	
	2012-2015	2016	Total <sup>2</sup>						
Programme budget	US\$ 615,018 <sup>3</sup>	US\$ 0	US\$ 615,018						
<b>10. Vaccine introduction grant:</b> Not applicable									
<b>11. Indicative annual amounts:</b> (subject to the terms of the partnership framework agreement) <sup>4</sup>									
<table border="1" style="margin-left: auto; margin-right: auto; border-collapse: collapse;"> <thead> <tr> <th style="width: 50%;"></th> <th style="width: 25%;">2012-2015</th> <th style="width: 25%;">2016</th> </tr> </thead> <tbody> <tr> <td style="padding: 2px;">Type of supplies to be purchased with Gavi funds in each year</td> <td style="padding: 2px;"></td> <td style="padding: 2px;"></td> </tr> <tr> <td style="padding: 2px;">Annual amounts</td> <td style="padding: 2px;">US\$ 615,018<sup>5</sup></td> <td style="padding: 2px;">US\$ 0</td> </tr> </tbody> </table>		2012-2015	2016	Type of supplies to be purchased with Gavi funds in each year			Annual amounts	US\$ 615,018 <sup>5</sup>	US\$ 0
	2012-2015	2016							
Type of supplies to be purchased with Gavi funds in each year									
Annual amounts	US\$ 615,018 <sup>5</sup>	US\$ 0							
<b>12. Procurement agency:</b> UNICEF									
<b>13. Self-procurement:</b> Not applicable									
<b>14. Co-financing obligations:</b> Not applicable									
<b>15. Operational support for campaigns:</b> Not applicable									

<sup>1</sup> This is the entire duration of the programme.

<sup>2</sup> This is the total amount endorsed by Gavi for the entire duration of the programme.

<sup>3</sup> This is the consolidated amount for all previous years.

<sup>4</sup> This is the amount that Gavi has approved.

<sup>5</sup> This is the consolidated amount for all previously approved years.

**16. Additional reporting requirements:** The Country shall deliver the following documents by the specified due dates as part of the conditions to the approval and disbursements of the future Annual Amounts.

Reports and other information	Due dates
To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.	15 May 2016
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat

**17. Financial clarifications:** Not applicable

**18. Other conditions:** Not applicable

Signed by,



**On behalf of Gavi**

Hind Khatib-Othman  
Managing Director, Country Programmes  
19 November 2015

## Zambia support for Pentavalent vaccine

This decision letter sets out the programme terms of a programme.

<b>1. Country:</b> Zambia			
<b>2. Grant number:</b> 16-ZMB-04a-X			
<b>3. Date of decision letter:</b> 19 November 2015			
<b>4. Date of the partnership framework agreement:</b> 22 October 2014			
<b>5. Programme title:</b> New vaccine support (NVS), Pentavalent Routine			
<b>6. Vaccine type:</b> Pentavalent			
<b>7. Requested product presentation and formulation of vaccine:</b> DTP-HepB-Hib, 1 dose per vial, LIQUID			
<b>8. Programme duration<sup>6</sup>:</b> 2005 - 2016			
<b>9. Programme budget (indicative):</b> (subject to the terms of the partnership framework agreement)			
	2005-2015	2016	Total <sup>7</sup>
Programme budget	US\$ 54,666,335 <sup>8</sup>	US\$2,650,500	US\$57,316,835
<b>10. Vaccine introduction grant:</b> Not applicable			
<b>11. Indicative annual amounts:</b> (subject to the terms of the partnership framework agreement) <sup>9</sup>			
Type of supplies to be purchased with Gavi funds in each year	2005-2015	2016	
Number of Pentavalent vaccines doses		1,402,400	
Number of AD syringes		1,461,600	
Number of safety boxes		16,100	
Annual amounts	US\$ 54,666,335 <sup>10</sup>	US\$ 2,650,500	
<b>12. Procurement agency:</b> UNICEF. The Country shall release its co-financing payments each year to UNICEF.			
<b>13. Self-procurement:</b> Not applicable			

<sup>6</sup> This is the entire duration of the programme.

<sup>7</sup> This is the total amount endorsed by Gavi for the entire duration of the programme.

<sup>8</sup> This is the consolidated amount for all previous years.

<sup>9</sup> This is the amount that Gavi has approved.

<sup>10</sup> This is the consolidated amount for all previously approved years.

**14. Co-financing obligations:** Reference code: 16-ZMB-04a-X-C

According to the co-financing policy, the Country falls within the group Preparatory transition.

The following table summarises the co-financing payments and quantity of supply that will be procured with such funds in the relevant year.

Type of supplies to be purchased with Country funds in each year	2016
Number of vaccine doses	318,800
Number of AD syringes	332,300
Number of safety boxes	3,675
Value of vaccine doses	US\$ 572,887
Total co-financing payments (including freight)	US\$ 602,500

**15. Operational support for campaigns:** Not applicable

**16. Additional reporting requirements:** The Country shall deliver the following documents by the specified due dates as part of the conditions to the approval and disbursements of the future Annual Amounts.

Reports and other information	Due dates
To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.	15 May 2016
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat

**17. Financial clarifications:** Not applicable

**18. Other conditions:** Not applicable

Signed by,



**On behalf of Gavi**

Hind Khatib-Othman

Managing Director, Country Programmes

19 November 2015

## Zambia support for Pneumococcal vaccine

This decision letter sets out the programme terms of a programme.

<b>1. Country:</b> Zambia			
<b>2. Grant number:</b> 16-ZMB-12b-X			
<b>3. Date of decision letter:</b> 19 November 2015			
<b>4. Date of the partnership framework agreement:</b> 22 October 2014			
<b>5. Programme title:</b> New vaccine support (NVS), Pneumococcal Routine			
<b>6. Vaccine type:</b> Pneumococcal			
<b>7. Requested product presentation and formulation of vaccine:</b> Pneumococcal (PCV10), 2 doses per vial, LIQUID			
<b>8. Programme duration<sup>11</sup>:</b> 2012 - 2016			
<b>9. Programme budget (indicative):</b> (subject to the terms of the partnership framework agreement)			
	2012-2015	2016	Total <sup>12</sup>
Programme budget	US\$ 26,244,940 <sup>13</sup>	US\$ 6,091,000	US\$ 32,335,940
<b>10. Vaccine introduction grant:</b> Not applicable			
<b>11. Indicative annual amounts:</b> (subject to the terms of the partnership framework agreement, if applicable) <sup>14</sup>			
Type of supplies to be purchased with Gavi funds in each year	2012-2015	2016	
Number of Pneumococcal vaccines doses		1,242,800	
Number of AD syringes		1,276,600	
Number of safety boxes		14,050	
Annual amounts	US\$ 26,244,940 <sup>15</sup>	US\$ 6,091,000	
<b>12. Procurement agency:</b> UNICEF. The Country shall release its co-financing payments each year to UNICEF.			
<b>13. Self-procurement:</b> Not applicable			

<sup>11</sup> This is the entire duration of the programme.

<sup>12</sup> This is the total amount endorsed by Gavi for the entire duration of the programme.

<sup>13</sup> This is the consolidated amount for all previous years.

<sup>14</sup> This is the amount that Gavi has approved.

<sup>15</sup> This is the consolidated amount for all previously approved years.

**14. Co-financing obligations:** Reference code: 16-ZMB-12b-X-C

According to the co-financing policy, the Country falls within the group Preparatory transition.

The following table summarises the co-financing payments and quantity of supply that will be procured with such funds in the relevant year.

Type of supplies to be purchased with Country funds in each year	2016
Number of vaccine doses	140,400
Number of AD syringes	143,900
Number of safety boxes	1,600
Value of vaccine doses (US\$)	US\$ 472,539
Total co-financing payments (including freight)	US\$ 484,500

**15. Operational support for campaigns:** Not applicable

**16. Additional reporting requirements:** The Country shall deliver the following documents by the specified due dates as part of the conditions to the approval and disbursements of the future Annual Amounts.

Reports and other information	Due dates
To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.	15 May 2016
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat

**17. Financial clarifications:** Not applicable

**18. Other conditions:** Not applicable

Signed by,



**On behalf of Gavi**

Hind Khatib-Othman

Managing Director, Country Programmes

19 November 2015

## Zambia support for Rotavirus vaccine

This decision letter sets out the programme terms of a programme.

<b>1. Country:</b> Zambia			
<b>2. Grant number:</b> 16-ZMB-13b-X			
<b>3. Date of decision letter:</b> 19 November 2015			
<b>4. Date of the partnership framework agreement:</b> 22 October 2014			
<b>5. Programme title:</b> New vaccine support (NVS), Rotavirus Routine			
<b>6. Vaccine type:</b> Rotavirus			
<b>7. Requested product presentation and formulation of vaccine:</b> Rotavirus, 2 dose schedule			
<b>8. Programme duration<sup>16</sup>:</b> 2013 - 2016			
<b>9. Programme budget (indicative):</b> (subject to the terms of the partnership framework agreement)			
	2013-2015	2016	Total <sup>17</sup>
Programme budget	US\$ 7,571,997 <sup>18</sup>	US\$ 1,892,500	US\$ 9,464,497
<b>10. Vaccine introduction grant:</b> Not applicable			
<b>11. Indicative annual amounts:</b> (subject to the terms of the partnership framework agreement) <sup>19</sup>			
Type of supplies to be purchased with Gavi funds in each year	2013-2015	2016	
Number of Rotavirus vaccines doses		837,000	
Annual amounts	US\$ 7,571,997 <sup>20</sup>	US\$ 1,892,500	
<b>12. Procurement agency:</b> UNICEF. The Country shall release its co-financing payments each year to UNICEF.			
<b>13. Self-procurement:</b> Not applicable			

<sup>16</sup> This is the entire duration of the programme.

<sup>17</sup> This is the total amount endorsed by Gavi for the entire duration of the programme.

<sup>18</sup> This is the consolidated amount for all previous years.

<sup>19</sup> This is the amount that Gavi has approved.

<sup>20</sup> This is the consolidated amount for all previously approved years.

**14. Co-financing obligations:** Reference code: 16-ZMB-13b-X-C

According to the co-financing policy, the Country falls within the group Preparatory transition.

The following table summarises the co-financing payments and quantity of supply that will be procured with such funds in the relevant year.

Type of supplies to be purchased with Country funds in each year	2016
Number of vaccine doses	129,000
Value of vaccine doses	US\$282,182
Total co-financing payments (including freight)	US\$290,000

**15. Operational support for campaigns:** Not applicable

**16. Additional reporting requirements:** The Country shall deliver the following documents by the specified due dates as part of the conditions to the approval and disbursements of the future Annual Amounts.

Reports and other information	Due dates
To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.	15 May 2016
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat

**17. Financial clarifications:** Not applicable

**18. Other conditions:** Not applicable

Signed by,



**On behalf of Gavi**

Hind Khatib-Othman

Managing Director, Country Programmes

19 November 2015